Study Goals Met For Genzyme And Isis

Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals Inc. (Nasdaq: ISIS) reported that a phase 3 clinical trial of their cholesterol treatment mipomersen met study goals but the stock prices fell. Genzyme lost 33 cents to $54.54 while Isis tumbled $1.58 to $9.46.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.